Scarica l'app Stockscreener
78.21
2.60%
-2.09
Dopo l'orario di chiusura:
79.77
1.56
+1.99%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ILMN Giù?
Forum
Previsione
Frazionamento azionario
Illumina Inc Borsa (ILMN) Ultime notizie
Illumina Inc (ILMN) CEO Jacob Thaysen Increases Stake with Recen - GuruFocus
Illumina Leadership to Share Strategic Vision at Prestigious Bernstein Conference May 28 - Stock Titan
Illumina unveils DRAGEN version 4.4 software focusing on oncology applications for clinical research - BioSpectrum India
Illumina, Inc. (ILMN): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying - Insider Monkey
South East Asia Molecular Diagnostics Market Forecast to 2031: PCR Technology Leads Growth, Kits & Reagents Hold Largest Share - GlobeNewswire Inc.
Onco-hematology Molecular Testing Market Top Players - openPR.com
Championing greater health in and outside the office - Illumina
NGS Library Preparation Market Growth Projections | Key Players: Illumina, Thermo Fisher Scientific, Roche - openPR.com
Illumina unveils DRAGEN v4.4 with enhanced accuracy - Investing.com
Illumina DRAGEN v4.4 powers clinical oncology research and multiomic applications - Illumina
Investing in Illumina (ILMN)? Don't Miss Assessing Its International Revenue Trends - Yahoo Finance
Illumina, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions - simplywall.st
Illumina, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - Yahoo Finance
Illumina Faces Uncertainties From China Ban, Research Slump, Morgan Stanley Says - marketscreener.com
Morgan Stanley Adjusts Illumina Price Target to $100 From $136, Maintains In Line Rating - marketscreener.com
Functional Genomics Market Top PlayersExact Sciences - openPR.com
Canaccord cuts Illumina stock target to $87, maintains hold By Investing.com - Investing.com India
Canaccord cuts Illumina stock target to $87, maintains hold - Investing.com
Illumina Q1 2025 revenue down 1% to USD 1.04 billion - Medical Buyer
Illumina outlines $4.18B to $4.26B guidance for 2025 amid China headwinds and strategic cost reductions - MSN
Illumina: Multiple Headwinds Point To Limited Upside In 2025 (NASDAQ:ILMN) - Seeking Alpha
Illumina (ILMN) Faces Adjusted Price Target and Positive Earnings Outlook | ILMN Stock News - GuruFocus
Illumina, Inc. (NASDAQ:ILMN) Q1 2025 Earnings Call Transcript - Insider Monkey
Cathie Wood’s ARK buys Shopify, Illumina stock; sells Palantir, Natera - Investing.com
Cathie Wood’s ARK buys Shopify, Illumina stock; sells Palantir, Natera By Investing.com - Investing.com India
Illumina (ILMN) Price Target Lowered by JP Morgan | ILMN Stock N - GuruFocus
SEC ends probe of Illumina’s Grail acquisition - MedTech Dive
TD Cowen raises Illumina stock target to $89, maintains Hold rating - Investing.com
Precision Medicine Market Analysis Report 2024-2030: Bristol-Myers Squibb, Illumina, Merck, AstraZeneca, and Roche Dominate with their Contributions to Research, Product Approvals, and Partnerships - GlobeNewswire
Illumina Q1 Earnings Top Estimates, Revenues Down Y/Y, Stock Dips - Yahoo Finance
Illumina Q1 2025 slides: Revises guidance downward amid China restrictions and tariff impacts - Investing.com
Lab-on-a-Chip Market Insights: Growth, Trends & Forecast - openPR.com
Illumina Inc (ILMN) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic ... By GuruFocus - Investing.com Canada
Earnings call transcript: Illumina Q1 2025 beats EPS forecast but faces stock dip - Investing.com
Illumina Reports Q1 2025 Financial Results Amid Challenges - TipRanks
Illumina: Q1 Earnings Snapshot - Norwalk Hour
Illumina (ILMN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Illumina confirms SEC has closed investigation into $8B Grail deal - Endpoints News
Illumina (ILMN) Tops Q1 Earnings and Revenue Estimates - Yahoo Finance
Illumina (ILMN) Shares Drop 3% Despite Beating Q1 EPS Estimates - GuruFocus
Illumina’s (NASDAQ:ILMN) Q1 Sales Top Estimates - Yahoo Finance
Illumina down 3% as lowered 2025 EPS guidance overshadows Q1 top-line beat - MSN
Illumina Cuts Guidance on Threat From Tariffs and China Ban - Bloomberg.com
Digital Genome Market Forecast: Growth Trends, Key Players & - openPR.com
Illumina Reports Financial Results for First Quarter of Fiscal Year 2025 - PR Newswire
Lobbying Update: $620,000 of ILLUMINA INC. lobbying was just disclosed - Nasdaq
Clinical Oncology Next-Generation Sequencing Market Size, - openPR.com
INVESTOR ALERT: Levi & Korsinsky Notifies Shareholders of Illumina, Inc.(ILMN) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Single Cell Genome Sequencing Market Deep Research 2025-2032 | - openPR.com
ILLUMINA Earnings Preview: Recent $ILMN Insider Trading, Hedge Fund Activity, and More - Nasdaq
Here’s Why Artisan Mid Cap Fund Decided to Exit Illumina (ILMN) - Insider Monkey
1.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):